首页> 外文期刊>Expert Review of Molecular Diagnostics >Molecular diagnostics of acute intermittent porphyria.
【24h】

Molecular diagnostics of acute intermittent porphyria.

机译:急性间歇性卟啉症的分子诊断。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Acute intermittent porphyria (AIP) is an inherited metabolic disease with an autosomal dominant pattern of inheritance. The disease is caused by a partial deficiency of porphobilinogen deaminase (PBGD) in heme biosynthesis. Since biochemical measurements of patients and their healthy relatives overlap, the diagnosis of AIP may remain undetermined at the symptom-free phase. Mutation detection in AIP, which provides 95% sensitivity and around 100% specificity, has quickly been incorporated into good clinical practice. During an acute attack, which includes various neurovisceral symptoms, measurement of urinary porphobilinogen (PBG) is a method of choice to confirm diagnosis, and DNA testing is unnecessary at that stage. DNA testing has revealed many new patients and excluded AIP from many healthy relatives despite slightly increased excretions of porphyrin precursors and erythrocyte PBGD in the low or borderline zone. Thus, quality-assured DNA testing is accurate enough to confirm or exclude the diagnosis of AIP. The clinical utility of DNA testing is limited for those individuals whose mutation is currently unknown, in which biochemical analyses are essential and the majority of the patients can be identified using urinary PBG and erythrocyte PBGD measurements. The measurement of urinary PBG can be used to evaluate the prognosis for symptom-free individuals. Currently, DNA testing of AIP at the population level is not recommended unless the frequency of gene carriers is locally very high and large-scale population-based mutation screening is reasonable. In the future, the knowledge of gene-gene and gene-environment interactions and protein networks using gene array and proteomics technologies may provide more precise information about pathogenetic mechanisms and novel therapeutic strategies for an acute attack and the long-term complications of AIP. Increasing knowledge of pharmacogenetics may identify the patients who are at high risk for clinical manifestations.
机译:急性间歇性卟啉症(AIP)是一种具有常染色体显性遗传模式的遗传性代谢疾病。该疾病是由血红素生物合成中的胆色素原脱氨酶(PBGD)部分缺乏引起的。由于患者及其健康亲属的生化测量值重叠,因此在无症状阶段对AIP的诊断可能仍不确定。 AIP中的突变检测可提供95%的灵敏度和大约100%的特异性,已迅速纳入良好的临床实践。在包括多种神经内脏症状的急性发作期间,测量尿液胆色素原(PBG)是确定诊断的一种选择方法,并且在该阶段无需进行DNA检测。 DNA检测已揭示出许多新患者,尽管在低或临界区中卟啉前体和红细胞PBGD的排泄量略有增加,但许多健康的亲属均排除了AIP。因此,有质量保证的DNA测试足够准确,足以确认或排除AIP的诊断。对于那些目前尚不知道突变的个体而言,DNA检测的临床应用是有限的,在这些个体中,生化分析是必不可少的,并且可以使用尿PBG和红细胞PBGD测量来识别大多数患者。尿PBG的测量可用于评估无症状个体的预后。目前,不建议在人群水平上进行AIP的DNA检测,除非基因载体的频率在当地非常高并且大规模基于人群的突变筛选是合理的。将来,使用基因阵列和蛋白质组学技术的基因-基因和基因-环境相互作用以及蛋白质网络的知识可能会提供有关AIP急性发作和长期并发症的致病机制和新治疗策略的更精确信息。越来越多的药物遗传学知识可能会识别出临床表现高风险的患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号